In summary, although HER2-targeted therapy has been found to improve short-term outcome in HER2-positive AGC, the success of such therapy achieved in HER2-positive breast cancer has not been reproduced in patients with AGC, highlighting the importance of understanding the mechanisms of resistance to HER2-targeted therapy in AGC. This evidence concerns the gene ERBB2 and breast cancer.